AU2020103170A4 - A delivery vector complex targeting respiratory mucosa and its application - Google Patents
A delivery vector complex targeting respiratory mucosa and its application Download PDFInfo
- Publication number
- AU2020103170A4 AU2020103170A4 AU2020103170A AU2020103170A AU2020103170A4 AU 2020103170 A4 AU2020103170 A4 AU 2020103170A4 AU 2020103170 A AU2020103170 A AU 2020103170A AU 2020103170 A AU2020103170 A AU 2020103170A AU 2020103170 A4 AU2020103170 A4 AU 2020103170A4
- Authority
- AU
- Australia
- Prior art keywords
- delivery vector
- mucosa
- application
- vector complex
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a delivery vector complex targeting animal respiratory mucosa
and its application. The delivery vector complex is prepared by mixing an appropriate amount
of the deliver vector deacetylated chitosan with an appropriate amount of adjuvant tetanus
toxoid. The presentation vector complex can be used together with the immunogens to produce
vaccines to prevent corresponding animal diseases. It solves the problem that the immune
complex vaccine targeting animal respiratory tract mucosa lacks effective delivery vector. It
improves the delivery efficiency of immune products targeting animal respiratory tract mucosa,
and enhances the immune response of respiratory tract mucosa. The application of the
invention technology can effectively protect animals from infectious diseases that are mainly
transmitted through respiratory mucosa, and increase the economic benefits of the livestock
industry.
Description
PATENTS ACT 1990
A delivery vector complex targeting respiratory mucosa and its application
The invention is described in the following statement:-
A delivery vector complex targeting respiratory mucosa and its application
The present invention relates to the technical field of animal biological preparations,
in particular to a preparation method of a deliver vector complex targeted to the respiratory
mucosal system of the animal, especially to a deliver vector complex targeted to respiratory
mucosal immunity and its application.
At present, there are live vaccines against infectious diseases caused by pathogenic
microorganisms mainly transmitted through animal respiratory tract, such as vaccines for
preventing mycoplasma infection in poultry, pigs, cattle and other animals, Newcastle
disease vaccines, infectious bronchitis vaccines, etc. These vaccines are characterized by
containing mucosal immunity and systemic immune response in animals through mucosal
immunity, thus protecting animals from foreign pathogen infection. However, some
pathogenic microorganisms, such as influenza virus and foot-and-mouth disease virus,
have no live attenuated vaccine, which makes the prevention and control of pathogens such
as influenza virus through respiratory tract lack of mucosal immune barrier - mucosal
resistance. The result of production practice is that, although the inactivated vaccine has
been used to immune animals to induce them to produce humoral immunity, the first
mucosal barrier of animals is open, so the pathogen can still infect and propagate in the
mucosa of the upper respiratory tract of the animals, which can not be eliminated in time.
Under the stress conditions, the animals can still be infected by influenza virus, thus
causing serious economic losses to the farms. This indicates that there is a need for
biological products or immune products aimed at preventing respiratory tract mucosal
infection. Secondly, at present, some chemical molecules such as liposomes, chitosan,
alginate and other vectors, as well as some derived from biological parts such as cholera
toxin, Escherichiacoli toxin, tetanus toxoid, can be used as adjuvants in vaccines. It can
overcome the limitation of extracellular barriers, protect immunogens from degradation by
extracellular nucleases, which can play an adjuvant role in promoting the recruitment and
activation of animal immune cells, so as to improve the immune response performance of
the body. Some substances, such as liposomes and chitosan, are delivery vectors, which
can play a role of delivery and transportation to a certain extent, and further enhance the
mucosal immunity of animals. There are also some technologies or reports about its
application in some biological products. And there are also some microorganisms which
can be used as vectors after being modified, such as Salmonella, lactic acid bacteria,
adenovirus and so on. Some of these carriers and adjuvants have been used in production
practice, but there is an urgent need for vaccines or immune complex technology for animal
mucosal immunity, which is prepared by combining the delivery vector with adjuvant
vector and immunogen (such as influenza virus). In other words, there is a lack of
corresponding delivery vectors and adjuvant complexes targeting mucosal immunity in
production.
In view of this, the technology of the present invention adopts the delivery vector
chitosan complex adjuvant tetanus toxoid (which is non-toxic to animals, and it can
effectively contact with the respiratory mucosa of animals, so that the exogenous material carried by it can fully contact with the cells on the mucous membrane surface of animals, and induce effective immune response) to form the adjuvant vector complex with chitosan delivery vector (which has better adjuvant property) to compensate for the lack of production technology to prepare products targeting the immunity of the respiratory mucosa of animals.
The technology of the invention can be effectively combined with immunogens (such
as screened inactivated H9N2 influenza virus) to form an immune complex vaccine
targeting mucous membranes. The vaccine can be applied to animals by nasal drops or
even spraying, which can improve the mucosal immune of animals, effectively prevent
animal diseases transmitted by respiratory mucosa, reduce the incidence of these diseases,
ensure animal health and increase economic benefits.
The purpose of the present invention is to provide a delivery vector compound for
targeting animal respiratory mucosa immunity, so as to solve the problem that there is no
good delivery vector complex for animal mucosal immunity in the prior art, thereby
providing technical support for developing a vaccine delivery vector targeting respiratory
mucosa. To conclude, it can effectively protect animals from diseases and improve the
economic benefits of aquaculture.
The present invention provides a delivery vector complex targeting respiratory tract
mucosa, which comprises screened adjuvant and the ratio of delivery vector.
The delivery carrier compound is prepared by dissolving a delivery carrier deacetylated chitosan with an appropriate mass and adjuvant tetanus toxoid with an appropriate mass in phosphate buffer solution, and mixing in a certain proportion when in use.
The delivery vector complex can be compounded with immunogen to prevent
corresponding animal diseases. When in use, a certain amount of adjuvant tetanus toxoid,
presentation carrier deacetylated chitosan and the immunogen are mixed evenly, then
adding freeze-dried protective agent and preservative, finally the immune complex vaccine
targeting animal respiratory tract mucosa is finished, which is ready for use.
A complete description will be given below in combination with the technical scheme
of the invention.
In the preparation of the vector composite, an analytical balance is used to weigh an
appropriate amount of deacetylated chitosan as the delivery vector which is dissolved in
phosphate buffer solution, at the same time, an appropriate amount of adjuvant tetanus
toxoid is dissolved in phosphate buffer solution, and the two solutions are reserved for later
use.
Preparation of immune complex-vaccine. The vaccine is prepared according to a
certain proportion, and a certain quality of adjuvant tetanus toxoid, delivery vector chitosan
and immunogen are respectively mixed evenly; Adding a certain amount of freeze-drying
protective agent. Then the deliver vector immune complex vaccine targeting respiratory mucosa is finished. The vaccine can be used to immunize animal fauna by nose or spray to prevent the corresponding diseases.
In general, the present invention provides a delivery carrier complex targeting the
respiratory mucosa of animals, which can be used as an immune adjuvant carrier for the
production or development of vaccine products targeting the respiratory mucosa after the
formation of the complex by adjuvant and delivery carrier. By targeting the mucosal system
of livestock and poultry, these products can induce the production of mucosal antibodies
and play a very good mucosal barrier immunity, so as to resist the animal diseases
transmitted mainly through the respiratory tract mucosal, such as influenza, mycoplasma
infection and so on, so as to protect animals and improve farm efficiency. In addition, it
can offset the shortage of current main immune products.
Finally, it should be noted that the above embodiments are only used to illustrate the
technical scheme, but not to limit it; Although the present invention has been described in
detail with reference to the foregoing embodiments, those of ordinary skill in the art should
understand that the technical solutions described in the foregoing embodiments can still be
modified, or some or all of the technical features can be equivalently replaced; However,
these modifications or substitutions do not make the essence of the corresponding technical
solutions deviate from the scope of the technical solutions of each embodiment of the
present invention.
Claims (3)
1. The delivery vector complex targeting animal respiratory mucosa and its
application, it is characterized in that it is an adjuvant delivery vector complex targeting
mucosal immunity in the respiratory tract of animals.
2. The delivery vector complex targeting animal respiratory mucosa and its
application, it is characterized in its composition of the delivery vector complex, the ratio
of adjuvant and delivery vector, as well as the preparation method. The delivery vector
complex targeting animal respiratory mucosal system can promote the full contact between
immunogen and mucosal cells, which can effectively stimulate animal mucosal immune
response, and play a portal immune effect.
3. The delivery vector complex targeting animal respiratory mucosa and its
application, it is characterized in its application of the delivery vector complex targeting
animal respiratory mucosa made by the method in production.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020103170A AU2020103170A4 (en) | 2020-11-02 | 2020-11-02 | A delivery vector complex targeting respiratory mucosa and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020103170A AU2020103170A4 (en) | 2020-11-02 | 2020-11-02 | A delivery vector complex targeting respiratory mucosa and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020103170A4 true AU2020103170A4 (en) | 2021-01-14 |
Family
ID=74103526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020103170A Ceased AU2020103170A4 (en) | 2020-11-02 | 2020-11-02 | A delivery vector complex targeting respiratory mucosa and its application |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2020103170A4 (en) |
-
2020
- 2020-11-02 AU AU2020103170A patent/AU2020103170A4/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11883489B2 (en) | Mucosal adjuvants and delivery systems | |
| KR20150102995A (en) | Nasal influenza vaccine composition | |
| CN102988981B (en) | Adjuvant for improving immunization effect of Edwardsiella vaccine and use method of adjuvant | |
| CN103740625B (en) | A kind of mycoplasmal pneumonia of swine attenuated live vaccine and application thereof | |
| US20240091349A1 (en) | Adjuvant for animal and human vaccines | |
| ZA200210402B (en) | Methods and composition for oral vaccination. | |
| Jin et al. | Response of live Newcastle disease virus encapsulated in N-2-hydroxypropyl dimethylethyl ammonium chloride chitosan nanoparticles | |
| RU2613672C2 (en) | Vaccine for protection of ruminant animals against pneumonia caused by pasteurella multocida | |
| CN101947321B (en) | Heat-resisting and freeze-drying protector for live vaccine and preparation method thereof as well as live newcastle disease vaccine | |
| AU2020103170A4 (en) | A delivery vector complex targeting respiratory mucosa and its application | |
| JP2012508221A (en) | Vaccine composition | |
| CN109833331B (en) | Preparation for killing mycoplasma hyopneumoniae and preparation method thereof | |
| CN104338128B (en) | A kind of vaccine combination and its preparation method and application | |
| CN111603566A (en) | Presentation carrier compound targeting respiratory mucosa and application | |
| WO2021021778A1 (en) | A composition for mucosal administration to avians | |
| CN109602902A (en) | One boar Pasteurella polysaccharide protein Conjugate vaccines and preparation method thereof | |
| CN106310248B (en) | Application of porcine pseudorabies virus live vaccine composition in treating porcine pseudorabies | |
| US20210402006A1 (en) | Nanoparticles and uses thereof | |
| CN117695385A (en) | Immunopotentiator, avian influenza vaccine, preparation method and application | |
| JPS6119607B2 (en) | ||
| TW201041591A (en) | Inactivated mixed vaccine for small viral infection of ducks and geese, duck viral hepatitis, and infectious serositis, and manufacturing method thereof | |
| Selina et al. | Microencapsulated DNA as a DNA-vaccine delivery system VI Balysheva1, NN Vlasova1, EA Markvicheva2, S. Yu. Belov1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) | ||
| MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |